Statements (85)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Dapagliflozin/_Metformin
gptkb:Dapagliflozin/_Metformin/_NPH gptkb:Dapagliflozin/_Metformin/_Sitagliptin gptkb:Glucophage |
| gptkbp:activities |
increases insulin sensitivity
inhibits glucose reabsorption |
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2014
gptkb:FDA |
| gptkbp:brand |
gptkb:Xigduo_XR
|
| gptkbp:class |
gptkb:drug
biguanide |
| gptkbp:clinical_trial |
ongoing
weight management Phase III glycemic control improved Hb A1c levels weight loss observed |
| gptkbp:contains |
gptkb:dapagliflozin
gptkb:metformin |
| gptkbp:contraindication |
metabolic acidosis
severe renal impairment diabetic ketoacidosis |
| gptkbp:dosage_form |
extended-release tablet
1 tablet once daily |
| gptkbp:duration |
as prescribed
|
| gptkbp:education |
monitor blood sugar levels
importance of diet and exercise |
| gptkbp:formulation |
gptkb:tablet
extended-release |
| https://www.w3.org/2000/01/rdf-schema#label |
Xigduo XR
|
| gptkbp:ingredients |
gptkb:metformin_hydrochloride
gptkb:dapagliflozin gptkb:metformin |
| gptkbp:interacts_with |
gptkb:Company
gptkb:ACE_inhibitors diuretics other antidiabetic agents other diabetes medications |
| gptkbp:is_available_in |
tablet form
various strengths |
| gptkbp:is_monitored_by |
renal function
blood glucose levels |
| gptkbp:is_used_for |
type 2 diabetes
|
| gptkbp:label |
contains patient information
|
| gptkbp:manufacturer |
gptkb:temple
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:packaging |
blister pack
|
| gptkbp:population |
adults
adults with obesity children over 10 years adults with type 2 diabetes |
| gptkbp:previous_name |
dapagliflozin and metformin
|
| gptkbp:provides_information_on |
EASD guidelines
ADA Standards of Medical Care |
| gptkbp:regulatory_compliance |
gptkb:Health_Canada
gptkb:EMA TGA |
| gptkbp:requires |
prescription only
|
| gptkbp:safety_features |
generally well tolerated
not for use in pregnancy not for use in breastfeeding risk of ketoacidosis monitor for dehydration risk of hypoglycemia low |
| gptkbp:scholarships |
stay hydrated
report signs of infection monitor kidney function |
| gptkbp:side_effect |
fatigue
nausea diarrhea lactic acidosis hypoglycemia hypotension urinary tract infection thirst pancreatitis increased urination genital mycotic infections |
| gptkbp:storage |
room temperature
|
| gptkbp:type_of_care |
important
|